Global Neurology Academy

Cladribine Receives Positive CHMP Opinion for Relapsing MS Treatment

    Merck KGaA, Darmstadt, Germany announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...
    • Overview

      Merck KGaA, Darmstadt, Germany announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of Cladribine Tablets (proposed tradename MAVENCLAD[TM]) for the treatment of relapsing forms of multiple sclerosis (RMS) in patients with high disease activity.

      To learn more about current and future treatment options for MS patients, click here

    Facebook Comments

    Sign-up for the Global Neurology Academy newsletters.
    Comprehensive Neurology Education.

    Better education for a better you.

    * Required
    Optional